Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nipocalimab DDI with Etanercept or HCQ in Healthy Participants
NCT04973566Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2021
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of nipocalimab in rheumatoid arthritis (RA), generalized myasthenia gravis (gMG), systemic lupus erythematosus (SLE) and 1 more (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Concentration (Cmax) of Etanercept, Area Under the Concentration-time Curve of Etanercept and 3 more. Started Aug 2021; status: completed.
02
Drugs
nipocalimab
03
Conditions
rheumatoid arthritis (RA)generalized myasthenia gravis (gMG)systemic lupus erythematosus (SLE)hemolytic disease of the fetus and newborn (HDFN)
Beyond the preview
Go deeper on NCT04973566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04973566.